Drugs / ubenimex
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02736149 | Dec 2016 → Mar 2018 | pulmonary arterial hypertension | Eiger BioPharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02700529 | Jun 2016 → Oct 2018 | lymphedema | Eiger BioPharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02664558 | Apr 2016 → Nov 2017 | pulmonary arterial hypertension | Eiger BioPharmaceuticals | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ubenimex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02736149 ↗ |
| Known as | (-)-bestatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL29292 ↗ |
| Known as | BESTATIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL29292 ↗ |
| Known as | NK-421 | ChEMBL registry synonym — accepted as the source's own label CHEMBL29292 ↗ |
| Known as | NSC-265489 | ChEMBL registry synonym — accepted as the source's own label CHEMBL29292 ↗ |
| Action | Inhibit | “Ubenimex is an inhibitor of leukotriene A4 hydrolase (LTA4H), the biosynthetic enzyme for LTB4.” NCT02700529 ↗ |
| Modality | Small molecule | — CHEMBL29292 ↗ |
| Route | Oral | “administered orally” NCT02664558 ↗ |
| Target | LTA4H | “Ubenimex is an inhibitor of leukotriene A4 hydrolase (LTA4H), the biosynthetic enzyme for LTB4.” NCT02700529 ↗ |